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trial
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Cliona McDowell8, Ashley Agus8, Lynn Murphy8 and Valerie J Page1,9*Abstract
Background: The incidence of delirium in ventilated patients is estimated at up to 82%, and it is associated with
longer intensive care and hospital stays, and long-term cognitive impairment and mortality. The pathophysiology
of delirium has been linked with inflammation and neuronal apoptosis. Simvastatin has pleiotropic properties; it
penetrates the brain and, as well as reducing cholesterol, reduces inflammation when used at clinically relevant
doses over the short term. This is a single centre randomised, controlled trial which aims to test the hypothesis that
treatment with simvastatin will modify delirium incidence and outcomes.
Methods/Design: The ongoing study will include 142 adults admitted to the Watford General Hospital Intensive
Care Unit who require mechanical ventilation in the first 72 hours of admission. The primary outcome is the number of
delirium- and coma-free days in the first 14 days. Secondary outcomes include incidence of delirium, delirium- and
coma-free days in the first 28 days, days in delirium and in coma at 14 and 28 days, number of ventilator-free days at
28 days, length of critical care and hospital stay, mortality, cognitive decline and healthcare resource use. Informed
consent will be taken from patient’s consultee before randomisation to receive either simvastatin (80 mg) or placebo
once daily. Daily data will be recorded until day 28 after randomisation or until discharge from the ICU if sooner.
Surviving patients will be followed up on at six months from discharge. Plasma and urine samples will be taken to
investigate the biological effect of simvastatin on systemic markers of inflammation, as related to the number of
delirium- and coma-free days, and the potential of cholinesterase activity and beta-amyloid as predictors of the risk
of delirium and long-term cognitive impairment.
Discussion: This trial will test the efficacy of simvastatin on reducing delirium in the critically ill. If patients receiving
the statin show a reduced number of days in delirium compared with the placebo group, the inflammatory theory
implicated in the pathogenesis of delirium will be strengthened.
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Trial registration: The trial was registered with the International Standard Randomised Controlled Trial Registry
(ISRCTN89079989) on 26 March 2013.
Keywords: Delirium prevention, Cognitive impairment, Statins, Beta-amyloidBackground
Delirium in critically ill patients is a manifestation of
acute brain dysfunction. The incidence of delirium in
mechanically ventilated patients, assessed using the Con-
fusion Assessment Method for the Intensive Care Unit
(CAM-ICU), is estimated at up to 82% [1]. Delirium and
dementia are typically presented as separate entities,
distinguished by the timing and duration of symptoms,
but increasingly are thought to share common patho-
logical mechanisms [2,3], Although the mechanisms by
which delirium may predispose patients to long-term
cognitive impairment after critical illness have not yet
been elucidated, delirium is associated with inflam-
mation and neuronal apoptosis, which may lead to brain
atrophy [4]. A longer duration of delirium has been
shown to be associated with worse global cognition at
three and 12 months after ICU discharge, and with
significantly higher ICU and hospital costs [5,6]. An
intervention which reduces delirium could potentially
translate to a reduction of long-term cognitive impair-
ment and dementia [7].
There is little evidence that commonly used pharma-
cologic approaches to prevent or treat delirium during
critical illness are effective [8,9]. Statins, in addition to
decreasing cholesterol synthesis, have complex pleio-
tropic effects and have been hypothesised to both pre-
vent and treat delirium via effects that may modulate
the molecular pathways of inflammation and microglial
activation [10].
An in vitro study comparing different statins for
prevention of neurodegenerative conditions concluded
that monacolin J derivatives (natural and semi-synthetic
statins), which includes simvastatin, are the best can-
didates. This is due to their better lipophilicity and
capacity to penetrate the blood–brain barrier, cholesterol-
lowering effect on neurons with a satisfactory safety
profile and in vitro protection against neuronal cell
death caused by okadaic acid [11]. The aim of the
Modifying Delirium Using Simvastatin (MoDUS) trial
is to test the hypothesis that treatment with enteral or
oral simvastatin (80 mg) will increase the number of
delirium- and coma-free days in ventilated ICU patients
up to 14 days. The effects of simvastatin treatment on
biological mechanisms important in the development of
delirium will also be explored, including inflammation
biomarkers, anticholinergic activity and beta-amyloid
(β-amyloid) [12,13].Methods/Design
West Hertfordshire Hospitals National Health Service
(NHS) Trust is the Sponsor for the MoDUS trial. The
trial will be conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki. The protocol is approved by the Newcastle
and North Tyneside 1 Research Ethics Committee (REC
reference: 12/NE/0383, 6 December 2012) and by the
Hertfordshire Hospitals Research and Development
consortium at Watford General Hospital. The trial is
registered on the International Standard Randomised
Controlled Trial Registry (ISRCTN89079989, assigned
on 26 March 2013). It is funded by the Research for
Patients Benefit programme, which is funded and man-
aged by the National Institute for Health Research
(NIHR). The trial is being coordinated by West Hert-
fordshire Hospitals NHS Trust, in partnership with
Northern Ireland Clinical Trials Unit (NICTU). The trial
will comply with the principles of Good Clinical Practice
(GCP) and will be carried out in accordance with applic-
able legislation and the Standard Operating Procedures
of West Hertfordshire Hospitals NHS Trust and the
NICTU. The trial will be reported in line with the Con-
solidated Standards of Reporting Trials (CONSORT)
2010 guidelines [14].
The MoDUS trial is a single centre, randomised,
double-blind, placebo-controlled, superiority phase II
trial including adults admitted to the Watford General
Hospital ICU who require mechanical ventilation in the
first 72 hours of admission. The study has three distinct
objectives: to investigate the efficacy of early statins ad-
ministration during an ICU stay for the prevention of
ICU delirium; to determine any improvement in related
neurocognitive sequelae coupled with standard clinical
outcomes; and to study the biological effect of simva-
statin on systemic markers of inflammation as related to
the number of delirium- and coma-free days, and the
potential of cholinesterase activity and β-amyloid as
predictors of the risk of delirium and long-term cognitive
impairment [12,13].
Eligibility criteria
Patients will be eligible for the trial if they fulfil the
following criterion: adult patients in intensive care
requiring intubation within the first 72 hours of admis-
sion. Patients fulfilling any of the criteria below will be
excluded from the trial:
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2. Patient known to be pregnant or breastfeeding;
3. Known allergy to statin drugs;
4. Creatine kinase (CK) level more than 10 times upper
limit of normal range within 72 hours of
randomisation;
5. Alanine transaminase (ALT) level more than eight
times the upper limit of normal range within 72
hours of randomisation;
6. Patients currently receiving ongoing and sustained
treatment with any of the following; itraconazole,
ketoconazole, HIV protease inhibitors, nefazodone,
cyclosporine, amiodarone, verapamil, diltiazem,
gemfibrozil or danazol;
7. Uncomplicated elective surgery (planned admission,
surgical procedure and recovery as predicted);
8. Patient expected to be discharged within 48 hours of
admission;
9. Patients with severe renal impairment (estimated
creatinine clearance less than 30 ml/minute) not
receiving renal replacement therapy;
10. Severe liver disease (Childs-Pugh score >12);
11. Current or recent treatment (within two weeks)
with statins, as statins will be continued assuming
there are no contraindications according to normal
unit practice;
12. Physician decision that a statin is required for
proven indication;
13. Contraindication to enteral drug administration,
such as patients with mechanical bowel obstruction
(patients with high gastric aspirates due to an ileus
are not excluded);
14. Known participation in investigational medicinal
product trials within previous 30 days;
15. Consent declined;
16. Treatment withdrawal likely within 48 hours;
17. Non-English speaking patients or those who do not
adequately understand verbal or written
information or
18. History of porphyria.
Clinical outcome measures
The primary outcome of the MoDUS trial will be the
number of delirium- and coma-free days in the first 14
days after randomization, during which the patient is
alive and free from delirium and coma, and where days
are counted as calendar days (from 00:00 to 23:59). The
coma state in an ICU patient is determined by nurses
using the Richmond Agitation and Sedation Score
(RASS) and delirium is screened for using the CAM-
ICU [15,16]. Patients are defined as delirious if they are
awake enough to at least respond to verbal stimulation
with eye opening and eye contact for less than 10
seconds (RASS score of −2) and screen positive fordelirium. CAM-ICU needs to be negative at all assess-
ments throughout a whole study day for the patient to
be considered free from delirium.
There are a number of secondary outcomes in this
trial, including: clinical outcomes, biological mecha-
nisms, safety measures and outcomes related to the
health economic evaluation. The clinical outcomes are
incidence of delirium, delirium- and coma-free days in
the first 28 days, delirium at 14 and 28 days, and days in
coma at 14 and 28 days. For this investigation, a RASS
score of −3, (movement or eye opening in response to
voice but no eye contact) regardless of whether disease
or sedative induced, is handled as part of the spectrum
of coma. While the validation studies for the CAM-ICU
have demonstrated that delirium can be diagnosed in pa-
tients with a RASS score of −3 at Watford, along with
some other centres, we routinely classify a patient with
such as score as unable to be assessed (usually due to
sedation). We decided this because of the clinical rele-
vance of a RASS score of −3 as shown by the Sedation
Practice in Intensive Care Evaluation (SPICE) Study In-
vestigators and ANZICS Clinical Trials Group who have
demonstrated that early deep sedation, defined as RASS
score −3 to −5, predicts delayed extubation and in-
creased mortality [17].
Other secondary outcomes are the number of
ventilator-free days at 28 days, mortality at six months,
organ failure-free days, cognitive decline and healthcare
resource use. Cognitive impairment at six months is
assessed using the telephone interview of cognitive sta-
tus, called Brief Test of Adult Cognition by Telephone
(BTACT), which is a battery of cognitive tests validated
for telephone use assessing immediate and delayed
memory recall, working memory span, verbal fluency,
inductive reasoning and speed of processing [18]. Cogni-
tive decline will be estimated by taking into account the
patient’s baseline cognitive function before admission to
the ICU, as assessed using the Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE), scored
at recruitment and six months later [19].
Biological mechanisms
A translational study of biological markers of inflamma-
tion, cholinergic activity and neurodegeneration to pro-
vide insight into the pathophysiology of delirium and the
potential of β-amyloid as a predictor of the risk of lon-
term cognitive impairment will be undertaken. Blood
and urine are taken at baseline prior to study drug ad-
ministration (day one), and on day three, seven, 14 and
28 (within 6 hours of study drug adminstration) while
the patients continue to receive the study drug. Plasma
inflammatory response biomarkers, which will include
serum C-reactive protein (CRP, cytokines (including
tumour necrosis factor alpha(TNF-α, interleukin (IL)-1,
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molecule expression, and coagulation factors will be ana-
lysed. In addition simvastatin plasma levels will be
analysed.
Plasma β-amyloid measurement has emerged as a
promising biomarker to identify elderly persons at risk
of developing dementia [20]. Lower β-amyloid 42 and
42/40 levels have been associated with increased risk of
developing Alzheimer’s disease. A study suggests that
older adults without dementia and with lower β-amyloid
42/40 levels have an increased rate of cognitive decline
over nine years compared with those with higher levels
[21]. It may be that plasma β-amyloid 42/40 levels may
be a predictor of those patients who are most at risk of
developing cognitive impairment following ICU delir-
ium, therefore serial β-amyloid 42 and 42/40 ratio levels
will be measured. Delirium is associated not only with
an unbalanced inflammatory response, but also with a
dysfunctional interaction between the cholinergic and
immune systems. In order to increase the understanding
of the relationship between the cholinergic and immune
systems with regard to delirium pathophysiology, we will
also measure biomarkers plasma acetylcholinesterase
and butyrylcholinesterase, as indicators of cholinergic
function [22].
Safety
Plasma will be collected from each patient on days three,
seven, 14, 21 and 28 while the patient is on the ICU, for
the purposes of safety monitoring. CK and ALT levels
will be measured. The frequency of the following events
will be reported: CK level over 10 times the upper limit
of normal; ALT level over eight times the upper limit of
normal; patients whose CK is elevated more than 10-
fold who then require renal replacement therapy; serious
adverse events (SAEs) and occurrence of suspected un-
expected serious adverse reactions (SUSARs). If the pa-
tient needs an acute administration of amiodarone
(manufacturer: Ibigen, Aprilia, Italy), the regime of the
study drug will be changed: the patient will receive one
tablet every other day.
Health economic evaluation
Health-related quality of life will be measured using the
EuroQol 5-dimension 5-level (EQ-5D-5 L) questionnaire
[23] at the point of consent to continue and at six
months post-randomisation, to calculate quality-adjusted
life years (QALY) at six months. Data on the health and
social care services used by all patients will be collected
for the six-month post-randomisation period. Length of
ICU stay (level three care), length of high dependency
unit stay (level two care) and length of hospital stay will
be recorded in the case report form (CRF), and patients
will use logs to record post-hospital discharge healthservice use. They will be asked to refer to this when
completing a questionnaire at six months. If question-
naires are not returned, non-responders will be con-
tacted by telephone and a second questionnaire will be
sent out if required. The cost-effectiveness of the treat-
ment compared to the placebo will be assessed.
Power and sample size estimate
The sample size calculation for this study has been ini-
tially based on data from the Awakening and Breathing
Controlled trial published in 2008, using the mean
delirium- and coma-free days of 10 at 28 days among
patients without the study intervention [24]. Our pilot
data showed a standard deviation of 4.14 in delirium
and coma free days at day 14 in a similar cohort (Shin-
tani A, personal communication, September 2012) As-
suming this standard deviation, and assuming a type I
error of 0.05 and 80% power, a sample size of 64 patients
per group is adequately powered to detect a difference
of approximately 2 DCFDs between the intervention and
control groups, or approximately 0.5 SD. Allowing for
an estimated 10% loss to follow-up, the sample size re-
quired is 142. nQuery AdvisoR version 4.0 was used for
the sample size analysis (Elashoff, JD 2000).
A flow chart for the protocol is outlined in Figure 1.
Trial conduct
The study will be conducted in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki. Critically ill patients requiring mechanical
ventilation within 72 hours of admission to intensive
care will be assessed for eligibility. A screening log will
be retained and anonymized. Written informed consent
or assent will be gained for patients fulfilling inclusion
criteria before beginning any research activities, which
include taking baseline bloods. Consent will be sought
from the patients themselves if this is possible, but it is
recognised that in the majority of cases ICU patients will
be unable to give informed consent due to delirium it-
self, or alterations in their level of consciousness caused
by illness and therapeutic sedation. In this situation,
consent will be sought from a personal legal representa-
tive (PerLR), who may be a relative, partner or close
friend, or a professional legal representative (ProfLR),
such as a doctor who is not connected with the conduct
of the trial. The consent from the representative will
remain valid until a decision on consent to continue is
obtained from the patient. All surviving patients that
regain capacity will be informed about the trial at the
earliest opportunity, and asked for consent to continue
the study. Patients may withdraw from the trial or be
withdrawn by their PerLR or ProfLR at any time, without
prejudice. Data recorded up to the point of withdrawal will
be included in the trial analysis. The IQCODE for each
Figure 1 Flow diagram (following CONSORT 2010 Statement Guidelines).
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family members or a friend at the time of consent and
recruitment. The patient registration form will be com-
pleted and submitted to the NICTU to confirm regis-
tration of the patient to the trial, in accordance with
the study drug randomisation schedule, and the unique
trial identifying number will be assigned at the time of
recruitment.
Patient drug packs will be prepared by Victoria Phar-
maceuticals (Belfast, UK), and distributed to the site.
The 142 consecutive packs will contain either sim-
vastatin or placebo according to a prearranged order
dictated by the 1:1 variable block randomisation sched-
ule decided by the use of a random number generator.
Simvastatin (40 mg tablets) or identical placebo tablets
will be packaged in a white opaque high-density poly-
ethylene plastic container, which will be sealed with a
tamper-evident seal and labelled in compliance with
applicable regulatory requirements. The placebo and ac-
tive tablets will be indistinguishable when crushed and
dispersed in water for nasogastric tube administration.Each container will contain 70 tablets of the study drug
for the treatment of one patient for 28 days (plus seven
days coverage). Each pack will be numbered with the
patient’s trial identifier. Treatment allocation will be
blinded as all trial drugs will be packaged identically and
identified only by a unique trial identifier. Recruited pa-
tients will be randomised to receive once daily sim-
vastatin (80 mg, as two 40 mg tablets) or two identical
placebo tablets administered enterally via a feeding tube
or orally for up to 28 days.
Although the primary outcome is determined at 14
days, the study drug will be administered for up to 28
days in order explore if longer treatment is associated
with sustained and greater effect; however, the 28 day
measurement will be less reliable given an expected
median ICU length of stay of nine days. The recruiting
clinician will complete a trial prescription form detailing
the unique trial identifier assigned to the patient at the
time of randomisation, which also corresponds to the study
drug pack to be prescribed. The first dose of the study
drug will be administered as soon as possible, ideally
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samples are collected, and subsequent doses will be
given at 12:00 am on the following calendar day. If, for
any reason, a dose is not administered at the intended
time, it may be administered subsequently, but not
more than 12 hours after the intended time of adminis-
tration. Any missed doses will be recorded in the CRF
to monitor treatment compliance.
Delirium assessment using CAM-ICU will be per-
formed twice by the bedside nurse per nursing shift,
with a minimum of four hours between assessments.
CAM-ICU is a routine assessment in all ICU patients,
and nurses undergo regular updates and have regular
access to advice from the ICU delirium study team.
Blood and urine samples will be taken at baseline prior
to study drug administration (day one) and on day
three, seven, 14 and 28 (within 6 hours of study drug
adminstration), while patients will continue to receive
the study drug for analysis of inflammatory cytokines,
β-amyloid and cholinesterase activity. The study drug
will be discontinued if any one of the following condi-
tions is met, prior to the maximum treatment period
(28 days from randomisation):
1. Study drug-related adverse event, defined as:
a. CK level over 10 times the upper limit of normal;
b. ALT level over eight times the upper limit of
normal.
2. Development of a clinical condition requiring
immediate treatment with a statin;
3. Discharge from the critical care environment;
4. Death;
5. Discontinuation of active medical treatment;
6. Patient or relative request that the study drug
should be discontinued or
7. Decision by the attending clinician that the study
drug should be discontinued on safety grounds.
At consent to continue, surviving patients who con-
sented to the follow-up protocol will be approached and
EQ-5D-5 L will be completed face-to-face. They will
receive a service use log to record their use of health
and social care services from hospital discharge until
six months post-randomisation. All survivors will be
contacted at six months by phone for an assessment of
cognitive function using the BTACT. Any deaths after
discharge from hospital will be identified using the
NHS Patient Centre Database, in order to avoid
contacting relatives of patients who have died. Trial
patients will be asked to let the Chief Investigator (CI)
know if they move house at any time after hospital
discharge; the NHS Patient Centre Database will enable
us to locate any who move without informing the CI.
Patients will be posted a follow-up package at sixmonths post-randomisation, which will include the
IQCODE, the EQ-5D-5 L and the use of health and so-
cial care services questionnaire.
Clinical management of patients in the trial
Patients involved in this trial will be managed according
to best practice established on the ICU. In patients
where there is a clinical indication for acute and imme-
diate treatment with a statin after randomisation, such
as an acute myocardial infarction, the study drug will be
discontinued and a statin commenced. The patient will
not be unblinded and data collection will continue. This
will be recorded on the CRF. The number and dose of
any antipsychotics or additional psychotropic drugs
given to a study patient in the first 28 days or before
discharge from the ICU (whichever is the earlier) will be
recorded in the CRF. The daily sedation goal for all
patients will be a RASS score of 0 to −1, unless a
patient’s clinical condition requires a deeper level of
sedation, such as a patient with severe acute respiratory
distress syndrome, or the patient is weaned from ventila-
tion. The sedative drugs used before patients are con-
sented for the study will be decided by the responsible
intensivist. Once they have consented to participate in
the study, patients will be maintained using fentanyl
(manufacturer: Hameln Pharmaceuticals, Gloucester, UK)
and propofol (manufacturer: UAB Norameda, Klaipeda,
Lithuania) infusions as needed while requiring ventilation.
The infusion rate will be titrated according to RASS
assessment and the nurse’s judgment of when a patient
is experiencing pain. Daily sedation breaks and daily
spontaneous breathing trials will be done at the discre-
tion of the consultant intensivist responsible for clinical
management, according to routine unit practice. The
sedative infusions will not be restarted as long as the
patient tolerates the interruption of sedation drugs.
Study procedures for unblinding
As a placebo-controlled, double-blind trial, patients
and clinicians will be blinded to each patient’s alloca-
tion. All trial drugs, whether simvastatin or placebo,
will be packaged identically and identified only by a
unique trial identifier. Any consultant intensivist may
request emergency unblinding on safety grounds. This
option should be used only if the patient’s future treat-
ment requires knowledge of the treatment assignment.
If a consultant decides that there is justification to
unblind a patient, they should attempt to contact the
CI or site co-investigator, who will arrange for them to
discuss the necessity of unblinding with a clinical mem-
ber of the trial team. Emergency unblinding will be
performed by the on-call pharmacist. The NICTU
should also be informed that unblinding has occurred.
All events will be logged.
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All study data for an individual patient will be re-
corded in the CRF. Patients are identified by initials
and their unique trial identifier, which was allocated
at the time of randomisation. Data will be collected
from the time the patients are enrolled into the trial
through to and following their discharge from hos-
pital, up to a maximum of six months following re-
cruitment. Any history of alcohol abuse will be
recorded if documented in the medical records. PRE-
diction of DELIRium in ICu patients (PRE-DELIRIC)
and daily Sequential Organ Failure Assessment
(SOFA) scores will be calculated using data from pa-
tients’ clinical notes. The PRE-DELIRIC is a validated
delirium prediction tool for adult intensive care pa-
tients [25]. The SOFA score will be used as daily se-
verity of illness assessment of ICU patients.
All completed CRFs will be forwarded to the NICTU,
and submitted data will be reviewed and processed as
per the NICTU Standard Operating Procedures. Due
care will be taken to ensure data safety and integrity,
and compliance with the Data Protection Act 1998. The
trial identifier, name, address and other contact details
of all patients who survive will be kept separately to
allow patients to be contacted at six months for the tele-
phone cognitive status evaluation, and for the follow-up
questionnaires to be posted to them. No patient-
identifiable data will be submitted to the NICTU. All
essential documentation and trial records will be stored
in conformance with the applicable regulatory require-
ments, and access to stored information will be re-
stricted to authorised personnel. Trial documentationTable 1 Definition of adverse events and reactions according
Term Definiti
Adverse Event (AE) Any unt
medicin
necessar
Adverse Reaction (AR) Any unt
related t
Unexpected Adverse Reaction (UAR) An adve
informat
of produ
Serious Adverse Event (SAE), Serious Adverse Reaction (SAR)
or Suspected Unexpected Serious Adverse Reaction (SUSAR)
Respecti
reaction
● results
● is life-
● requir
● results
● consis
● is any
of one
1For this trial it is anticipated that all women of child bearing age admitted will hav
pregnancy will be followed in order to assess the outcome regarding any adverse eand data will be archived for at least five years after
completion of the trial and as per sponsor requirements.
Pharmacovigilance
EU Clinical Trials Directive 2001/20 provides the defini-
tions of adverse events and reactions used in this trial
(Table 1).
Because this study is recruiting a population that is
already in a life-threatening condition, it is expected that
many of the participants will experience adverse events.
Events that are expected in this population (that is,
events that are in keeping with the patient’s underlying
medical condition) will not be reported as adverse
events. An adverse reaction is an adverse event which is
related to the administration of the study drug. If any
adverse reactions arise, they will be reported on the ad-
verse event form within the CRF. If an SAE thought to
be related with the study drug occurs, reporting will fol-
low the regulatory requirements and will be reported to
the NICTU and the sponsor within 24 hours of becom-
ing aware of the event. All SUSARs will be the subject of
expedited reporting.
End of trial
The trial will end when 142 patients have been recruited.
The Data Monitoring and Ethics Committee (DMEC)
will meet every nine months to determine whether there
is any reason why recruitment should not continue. In-
terim analyses will only be undertaken at the request of
the DMEC and will only be available to the DMEC. The
trial will be stopped prematurely if mandated by the
Ethics Committee, mandated by the Medicines andto EU clinical trial directive 2001/20
on
oward medical occurrence in a patient or clinical trial subject to whom a
al product has been administered, including occurrences which are not
ily caused by or related to that product.
oward and unintended response to an investigational medicinal product
o any dose administered.
rse reaction, the nature or severity of which is not consistent with the
ion about the medicinal product in question set out in the summary
ct characteristics (or Investigator brochure) for that product.
vely, any adverse event, adverse reaction or unexpected adverse
that:
in death
threatening
es hospitalization or prolongation of existing hospitalization
in persistent or significant disability or incapacity
ts of a congenital anomaly or birth defect1
other important medical event(s) that carries a real, not hypothetical, risk
of the outcomes above
e a pregnancy test. If, however, a subsequent pregnancy is discovered the
vent.
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Trial Steering Committee (TSC) or Sponsor after con-
sideration of recommendations from the DMEC or
funding for the trial ceases. The main criteria for early
stopping of the trial by the TSC upon suggestions from
the DMEC will be that evidence provided by the trial
investigators from the trial and from other sources
suggests: proof beyond all reasonable doubt that for all,
or for some types of patients, the treatment regimen is
clearly indicated or contraindicated, and evidence that
might reasonably be expected to influence routine clin-
ical practice.
Statistical analysis plan
Analyses of effectiveness endpoints will be on an intention-
to-treat basis. The primary outcome (delirium/coma free
days) is a heavily skewed distribution (bimodal with
peaks at 0 and 14 days) and the groups will initially
be analyzed by t-test with difference in means and
95% confidence intervals (CI) presented. A secondary
analysis of these outcome measures involving a boot-
strapped t-test will also be conducted to support the
findings of the t-tests and confirmed using the Mann–
Whitney non-parametric test. Dichotomous outcomes
will be analysed using risk ratios and 95% confidence in-
tervals, where appropriate. Continuous variables over
time will be analysed by generalised linear modelling.
Time to event outcomes such as duration of hospital
stay will be analysed by survival methods and reported
as hazard ratios and 95% CIs. Primary analyses will be
based on patients with outcome data (that is, available
case analysis). The randomisation process will ensure
balance in baseline variables. A detailed analysis plan
will be developed during the trial and submitted to the
DMEC for review prior to the commencement of ana-
lysis. All analyses will be conducted at the 5% level of
significance unless adjustment for multiple testing is
needed.
Health economic analysis
A within-trial cost-utility analysis (CUA) will be under-
taken by the health economist to assess the cost-
effectiveness of simvastatin compared with placebo in
the prevention and treatment of delirium. The perspec-
tive of the analysis will be the NHS and Personal Social
Services. The outcome of the CUA will be the cost per
QALY gained. Patients’ EQ-5D-5 L responses will be
presented as utility scores and used to calculate QALYs
at six months. Resource use will be valued using national
sources of unit costs, such as the NHS Reference Costs
and Personal Social Services Research Unit Costs of
Health and Social Care [26,27]. Multiple regression
models will be used to estimate mean costs and QALYs
for the six-month study period, adjusted for covariates.An incremental cost-effectiveness ratio will be calculated
to estimate the cost per QALY gained. Patient-level cost
and QALY data will be bootstrapped, and a cost-
effectiveness acceptability curve will be derived to show
the probability of simvastatin being cost-effective com-
pared to a placebo, at various thresholds of willingness-
to-pay for an additional QALY. Sensitivity analysis will be
performed to explore the impact on cost-effectiveness of
variations in key parameters. Given the study timeframe,
discounting will not be necessary.
Trial oversight
The CI will assume overall responsibility for ensuring
the trial is run in accordance with GCP and to the
highest ethical and scientific standards. West Hertford-
shire Hospitals NHS Trust Research and Development
Department will be responsible for overseeing the
financial management of the trial, and as Sponsors, for
ensuring that statutory regulations and reporting re-
quirements are fulfilled. Day-to-day management of the
trial will be undertaken by the local study team who
will liaise on monthly basis with the Trials Manage-
ment Group, composed of the CI and supporting staff
both at the site and at the NICTU.
The TSC will be comprised of experienced critical care
personnel and trialists, as well as a lay representative
from ICUsteps, an ICU patient support charity. This
charitable trust was founded in 2005 by ex-patients,
their relatives and ICU staff to support patients and their
families through the recovery from critical illness. The
TSC will take responsibility for major decisions, such as
a need to change the protocol for any reason, monitor-
ing and supervising the progress of the trial, reviewing
relevant information from other sources, considering
recommendations from the DMEC, and informing and
advising on all aspects of the trial. The DMEC (equiva-
lent to a North American Data Safety Monitoring Board)
will be appointed independently from the study team,
comprising of at least two clinicians with experience in
undertaking clinical trials and caring for critically ill
patients and a statistician. The study statistician will pro-
vide a report to the DMEC. The DMEC will function
primarily as a check for safety reviewing adverse events.
They will specifically review the incidence and severity
of side effects, SAEs and SUSARs, and produce a safety
recommendation following each meeting.
On-site monitoring visits will be undertaken by the
Clinical Trials Unit, and will be conducted in accordance
with the study monitoring plan. On-site monitoring will
be an ongoing activity from the time of initiation until
study close-out, and will comply with the principles of
GCP and EU directive 2001/20/EC.
Before the study starts, an initiation visit will take
place to ensure that all relevant essential documents and
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aware of the study protocol and Standard Operating
Procedures. During the study, on-site monitoring
visits will check the following: the completeness of
patient records; the accuracy of entries on CRFs; the
adherence to the protocol, Standard Operating Proce-
dures and GCP and the progress of patient recruit-
ment. Monitoring will also ensure that the study drug
is being stored, dispensed and accounted for accord-
ing to specifications.
Discussion
There is emerging evidence that statins may have a
beneficial role in the prevention and management of de-
lirium in the critically ill. A recent observational study in
critically ill patients found that statin use in the ICU was
associated with reduced delirium in the early stage of
sepsis, and later in their ICU stay if the patient was not
septic. This study confirms data from a UK cohort ana-
lysis of 470 consecutive ICU patients that showed a
similar decrease in daily risk of delirium following acute
statin administration [28,29] This benefit may be medi-
ated by a reduction of systemic inflammation.
Few small trials support a plausible anti-inflammatory
effect of statins used at clinically relevant doses over the
short term. One study in 42 patients comparing one
dose of 80 mg simvastatin with a placebo, demonstrated
significant reductions in serum median and mean CRP
concentrations measured 48 hours later [30]. In a trial
where a model of acute lung inflammation was induced
by inhalation of lipopolysaccharide in 30 healthy human
volunteers, simvastatin showed a reduction in systemic
inflammation [31] . Another trial compared 17 patients
who received standard therapy for unstable angina or
non-Q wave myocardial infarction with 13 patients also
given one dose of cerivastatin [32]. At 24 hours, the
patients treated with statin had significantly lowered
CRP levels.
However, there have been no randomized controlled
trials to investigate whether simvastatin prevents delir-
ium in critically ill patients. This trial will test the effi-
cacy of simvastatin 80 mg, administered enterally or
orally, on reducing delirium in the critically ill. The pri-
mary outcome of this study, the number of delirium-
and coma-coma free days, is pragmatic and clinically
relevant. It addresses the specific issues of mechanically
ventilated patients who cannot be assessed for delirium,
due to either sedation from a combination of drugs or
the patient’s underlying disease, while also accounting
for the possibility that a reduction in delirium days may
be a result of an increase in coma days, rather than a pa-
tient’s brain returning to normal function. In addition,
we aim to examine the mechanisms underlying any bio-
logical effects of simvastatin in delirium.For this study we have excluded patients prescribed
statins before admission as evidence from a multi-centre
randomised trial in patients with severe sepsis did not
support stopping statins. Prior statin users randomised
to receive placebo had higher 28 day mortality although
this was not statistically significant at 90 days. In
addition Morandi et al. in their observational study
showed that discontinuation of statins in patients was
associated with increased delirium.
The dosage of simvastatin administered in this placebo-
controlled trial was chosen based on data from a retro-
spective observational study of statin usage in patients
with sepsis, which showed a greater mortality benefit in
patients who were receiving a higher dose of statin [33]. A
nested cohort study found that statin therapy reduced
hospital mortality in patients with sepsis only when higher
doses of statins, in particular simvastatin, were given [34].
Moreover, simvastatin at a dose of 80 mg has been shown
to be well tolerated in acute lung injury patients, with no
increase in adverse events [35].
If the hypothesis that decreasing inflammation with
statins will decrease delirium is correct, then patients re-
ceiving the statin will show a reduced number of days in
delirium compared with the placebo group. Moreover,
the inflammatory theory implicated in the pathogenesis
of delirium will be strengthened.
Trial status
The MoDUS trial is ongoing, with 99 patients recruited as
of March 2015. Recruitment will continue to November
2016.
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